MAZD
Mazdutide
A synthetic acylated peptide based on the sequence of oxyntomodulin, a naturally occurring product of the proglucagon gene that acts at two receptors. It is an agonist at the glucagon receptor and the GLP-1 receptor.
Mazdutide has 12 registered human studies on ClinicalTrials.gov, reaching phase 4, covering 3,143 planned or enrolled participants across the 12 studies that published a figure. No FDA-approved product contains Mazdutide. 45 papers naming it were published in the last ten years.
Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Counts include only trials whose registered intervention names Mazdutide; the registry search is fuzzy, so every match is re-checked. None of this says whether Mazdutide works or is safe.
FDA status
Research only
Human studies
12
Furthest phase
Phase 4
Papers, 10 yr
45
Readership
1,109
monthly average, Feb–Jul 2026
Tracking since 2026-07-29 · About this data
What has actually been tested in humans
Reached phase 3 or 4, not approved
12
Registered human studies
Phase 4
Furthest phase reached
3,143
Planned or enrolled participants, across 12 studies that published a figure
None
No FDA-approved product contains it
36 loose registry matches were checked and 12 confirmed — 24 named something else and were discarded. We count a study only when Mazdutide is named as an intervention in it.
Registered means registered — not that the study finished, and not that it found anything. The grade is mechanical: it is computed from the registry and the FDA record alone, and it grades how much is known, never whether a compound is good or safe. Collected 2026-08-02 from ClinicalTrials.gov and Drugs@FDA. Check the query.
What Mazdutide is, and what it has been studied for
Mazdutide is classified by ChEMBL as a protein, and appears in trial registrations under IBI-362 and IBI362. Its FDA substance identifier is MB76Z4IBZ5.
Across 12 registered trials, it has been studied in Obesity, Type 2 Diabetes, Overweight and Obesity and Type 2 Diabetes Mellitus (T2DM). A condition here is what a sponsor registered the trial under — it records what was investigated, not what was shown.
The trials were run by Eli Lilly and Company and Shanghai Zhongshan Hospital among others. A named commercial sponsor means a compound is in formal development; its absence does not mean the opposite, only that no company has registered a trial under its own name.
How far it got
Mazdutide reached Phase 4 across 12 registered trials.
No FDA-approved product contains Mazdutide. A compound can stop at any rung for commercial reasons as easily as scientific ones, and the registry does not record which.
Is anyone studying Mazdutide?
Papers published each year that name Mazdutide in the title or abstract, with the clinical trials that started in the same year marked beneath. Ten calendar years.
| Year | Publications | Trials started | Complete year |
|---|---|---|---|
| 2017 | 0 | 0 | Yes |
| 2018 | 0 | 0 | Yes |
| 2019 | 0 | 0 | Yes |
| 2020 | 0 | 0 | Yes |
| 2021 | 0 | 0 | Yes |
| 2022 | 1 | 0 | Yes |
| 2023 | 1 | 1 | Yes |
| 2024 | 8 | 1 | Yes |
| 2025 | 20 | 3 | Yes |
| 2026 | 21 | 7 | No |
45 papers and 12 registered trials between 2017 and 2026. A paper counts when “Mazdutide” appears in its title or abstract — phrase-matched, so a paper mentioning the words separately is not counted. The total is a single query over the whole window, which is why it does not equal the bars added together: PubMed files a paper under both its electronic and its print publication date, so one paper can appear in two years. Publication volume measures scientific attention, not whether a compound works: a well-studied compound can be well-studied and ineffective. Sources: PubMed and ClinicalTrials.gov · collected 2026-08-02.
Published research on Mazdutide
45 indexed papers name Mazdutide in their title or abstract. These are the 8 PubMed ranks most relevant. Listing a paper is not a judgement about it, and none of these is summarised here — follow the link and read what it says.
- Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
- Emerging pharmacotherapies for obesity: A systematic review
- Mazdutide versus placebo in Chinese adults with type 2 diabetes
- Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
- A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity
- Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
- Mazdutide: First Approval
Collected 2026-08-02from PubMed, phrase-matched on “Mazdutide” in title and abstract. Run the same search.
About Mazdutide
A synthetic acylated peptide based on the sequence of oxyntomodulin, a naturally occurring product of the proglucagon gene that acts at two receptors. It is an agonist at the glucagon receptor and the GLP-1 receptor.
- Also known as
- IBI362 · LY3305677
Structure and mechanism only. Nothing above describes what this compound is for, and no dose appears anywhere on this page.
Reading on this compound
All articles →PepRack articles that reference this compound. This is not a news feed — we syndicate nothing and publish no datelines.
Vendor listings are not affiliate links and PepRack earns nothing from them. A listing records a price we observed on a date. It is not a recommendation of a product, dose, or treatment, and PepRack does not verify what any vendor ships.